Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Durgam Suresh K.

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/28/2020

3. Issuer Name and Ticker or Trading Symbol

Intra-Cellular Therapies, Inc. [ITCI]

(Last) (First) (Middle)

C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

NEW YORK, NY 10016

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8759	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	8/15/2028	Common Stock	62282	$0.00	D
Stock Option (right to buy)	⁽²⁾	1/8/2029	Common Stock	53967	$0.00	D
Stock Option (right to buy)	⁽³⁾	2/18/2030	Common Stock	33443	$0.00	D
Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Common Stock	26185	$0.00	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	25062	$0.00	D

Explanation of Responses:
(1)	On August 15, 2018, the reporting person was granted options to purchase 62,282 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
(2)	On January 8, 2019, the reporting person was granted options to purchase 53,967 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
(3)	On February 18, 2020, the reporting person was granted options to purchase 33,443 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
(4)	On January 8, 2019, the reporting person was granted 39,277 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
(5)	On February 18, 2020, the reporting person was granted 25,062 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:
Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Durgam Suresh K. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK, NY 10016			Chief Medical Officer